Abstract 6062
Background
A standardized evaluation approach in oncology is essential to optimize treatment and management of patients. In particular, a medical software designed to provide standard metrics and reports may help the communication among health care professionals, facilitating the decision process. To this aim, a large survey study was conducted across the United Kingdom (UK), Spain (ES) and Italy (IT) exploring existing unmet needs and questioning the way oncological data is tracked in daily routine practice with the aim of offering some ideas for improvement.
Methods
Physicians were enrolled by an independent Market Research Company according to diiferent inclusion criteria: a) 2-35 years in practice; b) ≥50% of practice time in direct patient care; c) involvement in making treatment decisions ; d) involvement in ordering and reviewing tumour assessment reports; e) to be an investigator or author of an oncology clinical trial in the past 5 years.The study was conducted in November-December, 2018.
Results
A total number of 270 physicians (medical oncologists: n = 180, radio-oncologists: n = 90) participated (UK/100, ES/95, IT/75). The vast majority of physicians use Response Evaluation Criteria in Solid Tumors (RECIST) criteria in their daily practice (86%). Guidelines for response criteria for use in trials testing immunotherapeutics (iRECIST) and modified RECIST (mRECIST) are also used by between third and a quarter of physicians. Of note, almost half of the physicians indicated that there is a low level of data management in oncology and 2 out of 3 agree that this negatively impacts therapeutic decisions. Over a third of ES physicians believe that there is a low level of data management in oncology and a similar proportion in IT and ES report that it is impacting therapeutic decision making.
Conclusions
Only a third of physicians view their current reporting systems as adequate. All participants agree that any reporting system is in need of a common shared template for radiologists and oncologists. Thus, physicians identify a lack of consistency in diagnostic assessments and delays in receiving the reports as key unmet needs in tumor reporting systems –indicating the need for a streamlined system.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Wehealth Digital Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract